Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma

PURPOSE: TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is preferentially activated in hypoxic conditions. This phase II study investigated TH-302 in combination with doxorubicin, followed by single-agent TH-302 maintenance therapy in patients with first-line adv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Chawla, Sant P., Cranmer, Lee D., Van Tine, Brian A., Reed, Damon R., Okuno, Scott H., Butrynski, James E., Adkins, Douglas R., Hendifar, Andrew E., Kroll, Stew, Ganjoo, Kristen N.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2014
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4588714/
https://ncbi.nlm.nih.gov/pubmed/25185097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.54.3660
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge